All News

CMS said Thursday that the average 2019 premium charged for the silver level of health insurance in the exchanges set up by the Affordable Care Act (ACA) dropped slightly for the first time since 2014, and Seema Verma, who heads CMS, credited the actions of the Trump administration for the lower premiums.

Senate Democrats were 1 vote short of overturning the Trump administration's expansion of short-term health plans; Celltrion’s CT-P10, a biosimilar to cancer drug Rituxan, received the unanimous support of an FDA advisory panel; Centene will enter 4 new states—North Carolina, Pennsylvania, South Carolina, and Tennessee—and expand offerings in 10 markets in 2019.

When consumers try to sign up for Affordable Care Act health plans on the federal marketplace, they may encounter hours-long downtime for the site; the United States–Mexico–Canada Agreement would increase pharmaceutical exclusivity from 8 years to 10 years, delay access to competition from biosimilar biologics; Medicare is considering paying for telemedicine for a 5-minute check-in call, but physicians question the proposal.

Under the current administration, CMS has made several good-faith attempts to revitalize the current healthcare system. These efforts demonstrate CMS’ commitment to move our industry closer to value-based payment and consumer-centered delivery models. However, each of these reforms exhibits concerning characteristics.

A recent study determined that patients with chronic obstructive pulmonary disease (COPD) and non-small cell lung cancer (NSCLC) had similar tumor microenvironment, but higher tumor infiltrating lymphocytes (TIL) exhaustion, than patients without COPD. The use of an anti-programmed cell death-1 (PD-1) antibody, nivolumab, was also demonstrated to be effective in this population.

According to the 2018 benchmark Kaiser Family Foundation Employer Health Benefits Survey, annual premiums for family and single coverage have increased in 2018 and the burden of deductibles continues to grow on employees. However, as premiums rise, so does employer investment in health and wellness programs for their employees.

Last week, the FDA granted approval to immune checkpoint inhibitor cemiplimab-rwlc, to be sold as Libtayo, for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), or in patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.

A medical social network for physicians said it has compiled data that pinpoint the top 50 metropolitan areas where shortages of oncologists are expected to occur in the coming years. Doximity said the findings in its 2018 National Oncologists Workforce report are drawn from retirement trends, the percentage of state-trained specialists, and the prevalence of breast cancer.

The Reagan-Udall Foundation for the FDA, a little-known nonprofit set up by Congress over 10 years ago to help the agency work with the private sector, is still struggling with funding as well as questions about its mission; the preferences of millennials are changing the traditional model of office-based primary care; Democrats are planning to force a vote in the Senate this week on overturning a Trump administration rule expanding short-term health insurance plans.

Some patients with chronic obstructive pulmonary disease (COPD) experience a sudden worsening of their symptoms that require additional treatment—also known as acute exacerbation of COPD (AECOPD). A recent study, which investigated whether readmissions of patients with severe AECOPD varied according to the bacterium or virus identified, found that P. aeruginosa identification is associated with a higher readmission rate in patients.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo